Sen. Gillibrand: HELP Committee passes bipartisan CLEAR LABELS Act to require drug origin disclosures

U.S. Sen. Kirsten Gillibrand (D-N.Y.) and Sen. Rick Scott (R-Fla.) announced July 23 that the Senate Health, Education, Labor and Pensions Committee approved the bipartisan CLEAR LABELS Act, legislation that would require prescription drug labels to disclose where active pharmaceutical ingredients (APIs) and finished drugs are manufactured.

The bill passed the HELP Committee by a 21-1 vote and now moves to the full Senate. According to the senators’ announcement, the legislation — Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) — is intended to give patients, pharmacists and providers information about drug origins to strengthen accountability across the supply chain.

What the bill would do

The CLEAR LABELS Act would add country-of-origin and original manufacturer disclosure requirements to the U.S. prescription drug supply chain, including for active pharmaceutical ingredients. Supporters say the measure aims to improve transparency and help identify vulnerabilities where drugs or ingredients are manufactured overseas.

Senators’ statements

Sen. Gillibrand said the measure would make information about where prescription drugs are manufactured “readily accessible to patients, pharmacists, purchasers, and providers” and that she will continue pressing for full congressional passage.

Sen. Scott described committee passage as “a massive win for consumer safety and transparency,” saying the legislation responds to concerns raised by Senate committee work about foreign sources of generics and APIs.

Next steps and context

With committee approval complete, the bill heads to the full Senate. The public text of the bill is available from the sponsoring office. The senators highlighted that many drugs and APIs are produced overseas — particularly in China and India — and that current federal labeling rules do not require disclosure of manufacturing origins.

Senate offices say the measure is intended to give regulators, providers and patients better visibility into the drug supply chain. Additional details about implementation, enforcement, or expected timelines for a floor vote were not included in the announcement.

Source: U.S. Sen. Kirsten Gillibrand press release. Full bill text: https://www.gillibrand.senate.gov/wp-content/uploads/2026/02/CLEAR-LABELS-Act.pdf

Related articles

Trump Backs Off On Punishing China Over His Claims They Meddled in 2020 Election: It Was ‘A Long Time Ago’

President Donald Trump appeared to back off on holding China accountable after he claimed last week that the regime meddled in the 2020 election.

The post Trump Backs Off On Punishing China Over His Claims They Meddled in 2020 Election: It Was ‘A Long Time Ago’ first appeared on Mediaite.

Headlines for July 23, 2026

House GOP Approves $73B in New Pentagon Funding, $10B...

Sen. Gillibrand demands strategy after U.S. troop deaths in Iran war

Sen. Kirsten Gillibrand criticized the administration after three U.S. troops were killed over the weekend in the Iran war, saying the conflict lacks a clear objective or exit strategy and calling for answers.

Epstein’s ‘friendship’ with Trump at center of ‘major security liability’: leading Dem



Rep. Jamie Raskin (D-MD) issued a fierce demand Monday to Acting Attorney General Todd Blanche regarding President Donald Trump’s “long-term friendship” with Jeffrey Epstein, arguing it may have not only influenced the Trump administration’s policies, but created a “major national security liability.”

Raskin's demand came in the form of a letter to Blanche's office requesting records on Epstein's foreign ties, details of which have emerged through the Justice Department's release of millions of Epstein-related files that started last year. Specifically, Raskin’s request centered around suspicions that Epstein acted as a “foreign agent” for multiple countries, and on some occasions, did so “in order to influence policies of the first Trump administration.”

“Given the information Mr. Epstein possessed about President Trump and his easy access to high-level officials in the President’s inner circle, Mr. Epstein’s relationships with foreign leaders, including adversaries, posed a major national security liability,” Raskin’s letter reads.

Raskin, the top Democrat on the House Judiciary Committee, released the letter publicly on Tuesday, in which he cited evidence suggesting that Epstein worked on behalf of Saudi Arabia, Kuwait, Russia and Israel, a potential violation of the Foreign Agents Registration Act (FARA).

Raskin went on to detail several examples as to how Epstein’s friendship with Trump may have created a legitimate “security risk” to the United States, including one involving a “Russian oligarch.”

“Mr. Epstein privately alleged the President was involved in an international money laundering scheme with a Russian oligarch that centered around real estate in Florida. In another missive, Mr. Epstein connects the dots between this scheme and the sale of expensive artwork to [Saudi Arabian Crown Prince Mohammed bin Salman],” Raskin’s letter reads.

“While Mr. Epstein was prone to exaggeration and self-aggrandizement, these emails suggest President Trump’s foreign business interests may have had a tangible effect on foreign policy and that Mr. Epstein knew about and was willing to weaponize such lurking and explosive conflicts of interest.”

Raskin demanded that Blanche's office turn over “all records” related to Epstein and 19 different countries, as well as all records relating to entities associated with Epstein that “may have been set up to avoid their foreign contacts triggering personal FARA registration requirements.”

In the letter, Raskin noted that Epstein, alongside former Trump official Steve Bannon, appeared to employ “strategies for skirting FARA’s requirements,” including the use of non-profit entities and other non-governmental organizations to structure “international arrangements,” and to “use go-betweens so he could remain ‘surgically pure.’”